

Registration number: 07110945

LGC Science Group Limited Annual report and accounts

31 March 2019



LGC Science Group Limited

Directors

Timothy Robinson
Simon Parsons

Secretary

Navneet Ogle

Registered Address

LGC
Queens Road
Teddington
Middlesex
TW11 0LY

LGC Science Group Limited

Strategic report

The Directors present their strategic report for the year ended 31 March 2019

Principal activity

LGC Science Group Limited ("the Company") principal activity during the year is that of a holding company. The Company expects to continue to operate on the same basis for the foreseeable future. The main trading entity of that wider group is LGC Science Group Holdings Limited ("the Group" or "LGC"), a company incorporated in England.

LGC is a global leader in the life science tools sector, serving customers in human healthcare, applied markets (including food, agbio and the environment), research and government. LGC provide a comprehensive range of reference materials, proficiency testing schemes, oligonucleotides, genomics reagents and instrumentation based upon our foundation of research and measurement capabilities. Our scientific tools and solutions form an essential part of our customers' quality and compliance procedures as well as enable them to provide safer products, develop new solutions and advance research.

The Group operates via the Standards and Genomics divisions, underpinned by our Health, Science & Innovation (HS&I) team and our corporate functions.

Each division provides mission critical solutions in life sciences tools and technology across growing end markets. The business model includes research and development, manufacturing, marketing, sales and customer support of a range of specialist products underpinned by our science capabilities.

The Standards division provides a comprehensive product range of Measurement Tools, Proficiency Testing schemes and Supply Chain Assurance tools.

The Genomics division provides a comprehensive product range of Oligonucleotides, PCR (Polymerase Chain Reaction) reagents and instrumentation and NGS (Next Generation Sequencing) tools.

Our HS&I team runs a number of national, scientific laboratories on behalf of the British Government along with leading analytical and measurement capabilities for pharma customers in the development of nucleic acid therapeutics and small and large molecule drugs.

The business addresses markets which are underpinned by sustainable growth drivers such as population demographics, rise of the middle class, increased regulatory activity and a continuing demand for a high quality of life.

Science for a safer world is our core purpose. Our strategy is to build sustainable leading positions in attractive niche segments requiring specialist scientific expertise, across the life science tools sector, including clinical and molecular diagnostic, pharma & biotech and applied markets (food & environment, agri-genomics, industrial and metals). In doing so we will leverage our position as a global leader in life science tools and technology, our world-class measurement science capabilities, and our highly differentiated and complete portfolio of products and technologies and our proven capability in delivering organic and inorganic growth.

A full review of the business of which LGC Science Group Limited forms a part and future developments are disclosed in the financial statements of LGC Science Group Holdings Limited, which are available to the public and may be obtained from LGC, Queens Road, Teddington, Middlesex, TW11 0LY.

Ownership

LGC's ultimate controlling party is KKR & Co L.P. ("KKR"), an entity incorporated in the United States of America. KKR acquired their controlling interest through various subsidiary entities including KKR Blue Co-Invest L.P. and KKR European Fund IV L.P. Founded in 1976, KKR is a leading global investment firm, listed on the New York Stock Exchange, with approximately \$200 billion in assets under management and with deep roots in private equity. KKR has a long history of successfully investing in science and healthcare businesses, including investments such as Alliance Boots, Adocia, HCA, Jazz Pharmaceuticals, Panasonic Healthcare, PRA International, BridgeBio Pharma, Coherus Biosciences and Slayback Pharma. KKR bring decades of financial, operational and consultancy experience, strong strategic, sector and market knowledge and a powerful network of global relationships.

LGC Science Group Limited

Strategic report (continued)

Review of the business and future developments

The income statement is set out on page 6, and shows the loss for the financial year of £8,049,000 (2018 – loss of £22,461,000)

No key performance indicators are monitored by the Directors as LGC Science Group Limited is a holding company

Principal risks and uncertainties

The review of other principal risks and uncertainties contains certain forward looking statements. These statements have been made by the Directors in good faith based on the information available to them at the time of their approval of this report. They should be treated with caution due to the inherent uncertainties arising because they relate to circumstances that may or may not occur in the future. The principal risks facing the Company are grouped broadly into competitive and financial instrument risks

Financial instruments

Financial risk management

The Company's operations expose it to a variety of financial risks that include the effects of changes in price risk, credit risk, liquidity risk, interest rate cash flow risk and foreign exchange risk. The Company's main UK trading parent, LGC Science Group Holdings Limited, has in place a group-wide risk management programme that seeks to limit the adverse effects on the financial performance of the Company. Details are set out in the financial statements of LGC Science Group Holdings Limited

Liquidity risk

Liquidity is managed by the main UK trading parent, LGC Science Group Holdings Limited. The wider Group actively maintains a mixture of long-term and short-term debt finance and cash deposits that are designed to ensure the Group has sufficient available funds for operations, expansion and planned acquisitions. From 8 March 2016, there are no liquidity covenants associated with the Company's banking facilities

Foreign exchange risk

The Company is exposed to cash flow risk as a result of assets and liabilities denominated in foreign currency. This risk is partially mitigated by internally generated cash flows in a similar mix of currencies. Net risk of exposure to operations in foreign currencies is managed by the purchase of forward foreign exchange contracts



Simon Parsons

Director

18 December 2019

LGC Science Group Limited

Directors' report

The Directors present their report and financial statements for the year ended 31 March 2019

Directors

The Directors who served the Company during the year and up until the date of approval of these financial statements were as follows

Timothy Robinson

Simon Parsons

Dr Derek Craston

(resigned 15 August 2018)

Key person and Directors and Officers insurance is maintained for all Directors

Dividends

The Directors do not recommend an interim dividend or final dividend (2018 £nil)

Going concern

The financial statements have been prepared on the going concern basis

In considering the appropriateness of the going concern assumption, the Directors have had regard to

- financial support from LGC Science Group Holdings Limited (the ultimate UK trading parent company),
- future projections for the Company and the Group, and
- financing arrangements in place

The Group has loan facilities to provide adequate financing to support the Company's operations and the covenants set out in the Group's facilities are forecast to continue to be satisfied

Whilst acknowledging the inherent risk in any plan, the Directors are concluding that, having considered the factors set out above, it is appropriate to prepare the financial statements on a going concern basis

Events since the balance sheet date

On 20 November 2019 the shareholders' of LGC agreed to the sale of LGC to a consortium jointly lead by Astorg and Cinven

Financial instruments

Details of financial instruments are provided in the strategic report on page 3

By order of the Board



Simon Parsons

Director

18 December 2019

LGC Science Group Limited

Directors' responsibilities statement

The Directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 101 'Reduced Disclosure Framework' ('FRS 101'). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the Directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgments and accounting estimates that are reasonable and prudent,
- state whether FRS 101 has been followed, subject to any material departures disclosed and explained in the financial statements, and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

LGC Science Group Limited
Income Statement
for the year ended 31 March 2019

		2019	2018
	Notes	£000	£000
Other external charges		182	(345)
Operating profit / (loss)	3	182	(345)
Interest receivable from Group undertaking		200	-
Interest payable to Group undertakings		(8,431)	(22,116)
Loss on ordinary activities before taxation		(8,049)	(22,461)
Tax on loss on ordinary activities	5	-	-
Loss for the financial year		(8,049)	(22,461)

All activities in the period relate to continuing operations

Statement of comprehensive income
for the year ended 31 March 2019

		2019	2018
	Notes	£000	£000
Loss for the financial year		(8,049)	(22,461)
Total comprehensive income for the year, net of tax		(8,049)	(22,461)

LGC Science Group Limited

Registered No 07110945

Balance sheet

at 31 March 2019

	Notes	2019 £000	2018 £000
Fixed assets			
Investments	6	221,276	221,276
Current assets			
Debtors	7	2,573	2,393
Creditors : amounts falling due within one year	8	(2,203)	(2,227)
Net current assets		370	166
Total assets less current liabilities		221,646	221,442
Creditors : amounts falling due after more than one year	9	(111,414)	(103,161)
Net liabilities		110,232	118,281
Capital and reserves			
Share capital	10	161,091	161,091
Share premium		58,832	58,832
Retained earnings		(109,691)	(101,642)
Shareholders' funds		110,232	118,281

For the year ending 31 March 2019 the Company was entitled to exemption from audit under Section 479A of the Companies Act 2006 relating to subsidiary companies

The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts



Simon Parsons

Director

18 December 2019

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

1. Corporate information

These financial statements were authorised for issue by the Board on 18 December 2019. The Company is a private company limited by share capital incorporated in England and Wales and domiciled in the United Kingdom.

The address of its registered office is

LGC
Queens Road
Teddington
Middlesex
TW11 0LY

2. Accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Basis of preparation

The Company's financial statements,

- have been prepared under the historical cost convention and in accordance with FRS 101 and the Companies Act 2006,
- do not comply with all of the disclosure requirements of EU-adopted IFRS and therefore do not contain the unreserved statement of compliance set out in paragraph 3 of IFRS 1 First Time Adoption of International Financial Reporting Standards and paragraph 16 of IAS 1 Presentation of Financial Statements,
- are presented in pounds sterling and all values are rounded to the nearest thousand pounds (£000), except where indicated otherwise,

The Company has taken advantage of the following disclosure exemptions under FRS 101 -

- the requirements of IFRS 7 Financial Instruments Disclosures,
- the requirements of paragraphs 91-99 of IFRS 13 Fair Value Measurements,
- the requirement in paragraph 38 of IAS 1 'Presentation of Financial Statements' to present comparative information in respect of
 - (i) paragraph 79(a)(iv) of IAS 1,
 - (ii) paragraph 73(e) of IAS 16 Property, Plant and Equipment,
- the requirements of paragraphs 10(d), 10(f), 39(c) and 134-136 of IAS 1 Presentation of Financial Statements,
- the requirements of IAS 7 Statement of Cash Flows;
- the requirements of paragraphs 30 and 31 of IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors,
- the requirements of paragraph 17 of IAS 24 Related Party Disclosures, and
- the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member.

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

2. Accounting policies (continued)

Exemption from preparing group accounts

The financial statements contain information about LGC Science Group Limited as an individual Company and do not contain consolidated financial information as the parent of a group

The Company is exempt under section 400 of the Companies Act 2006 from the requirement to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of LGC Science Group Limited, a company incorporated in England and Wales

Going Concern

The financial statements have been prepared on a going concern basis as per the Directors' report

In considering the appropriateness of the going concern assumption, the Directors have had regard to

- financial support from LGC Science Group Holdings Limited (the ultimate UK trading parent company),
- future projections for the Company and the Group, and
- financing arrangements in place

The Group has loan facilities to provide adequate financing to support the Company's operations and the covenants set out in the Group's bank facilities are, and are forecast to continue to be, satisfied

Whilst acknowledging the inherent risk in any plan, the Directors are concluding that, having considered the factors set out above, it is appropriate to prepare the financial statements on a going concern basis

New and amended standards and interpretations

The Company applied IFRS 15 and IFRS 9 for the first time. The nature and effect of the changes as a result of adoption of these new accounting standards are described in note 24

Several other amendments and interpretations apply for the first time in 2019, but do not have an impact on the financial statements of the Company. The Company has not early adopted any standards, interpretations or amendments that have been issued, but are not yet effective

Interest receivable and interest payable

Income is recognised as interest accrues using the effective interest rate method, that is, the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument to the net carrying amount of the financial asset. Where loans are repayable on demand interest is charged / credited at the agreed intercompany rate

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates. All differences arising on settlement or translation of monetary items are taken to the Income statement. Tax charges and credits attributable to exchange differences on those monetary items are also recorded in the Income statement

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates taxable income

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

2. Accounting policies (continued)

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the Company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Fixed asset investments

Fixed asset investments are stated at cost. The carrying values of fixed asset investments are reviewed for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

In the event of reconstructions within the Group, where the trade and net assets of subsidiary undertakings may be transferred elsewhere within the Group, consideration is given to whether such reconstruction results in a loss to the Company when considering whether an impairment has occurred.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3. Operating profit / (loss)

The profit / (loss) for the year is entirely from continuing operations.

4. Staff costs and Directors remuneration

The Directors of the Company are also Directors of the holding Company and fellow subsidiaries. The Directors received total remuneration for the year of £1,185,000 (2018: £1,200,000), which was paid by LGC (Holdings) Limited. The Directors do not believe that it is practical to apportion this amount between their services as Directors of the company and services as Directors of the holding and fellow subsidiary companies.

Other than the Directors, the Company had no employees and therefore incurred no staff costs during the year.

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

5. Taxation

Tax charged in the income statement

(a) Analysis of charge in year:

	2019	2018
	£000	£000
Current tax		
UK tax charge for the year	-	-
Total tax charge for the year	-	-

(b) Factors affecting tax charge for the year:

The tax on loss before tax for the year is higher than the standard rate of corporation tax in the UK of 19% (2018 19%) The differences are reconciled below

	2019	2018
	£000	£000
Loss on ordinary activities before taxation	(8,049)	(22,461)
Corporation tax at standard rate of 19%	(1,529)	(4,268)
Effects of		
Expenses not deductible for tax purposes	-	4,203
Group relief received for nil payment	1,529	65
Total tax for the year	-	-

(c) Deferred tax assets and liabilities

The Company has tax losses carried forward at 31 March 2019 of £nil (2018 £nil)

(d) Factors that may affect future tax charges

At Summer Budget 2015, the government announced legislation setting the Corporation Tax main rate at 19% for the years starting the 1 April 2017, 2018 and 2019 and at 18% for the year starting 1 April 2020. At Budget 2016, the government announced a further reduction to the Corporation Tax main rate (for all profits except ring fence profits) for the year starting 1 April 2020, setting the rate at 17%.

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

6. Investments

	2019 £000	2018 £000
At 1 April	221,276	162,444
Additions	-	58,832
At 31 March	221,276	221,276

As at 31 March 2019 details of the investments in which the Company holds 20% or more of the nominal value of any class of share capital are as follows

Subsidiary	Registered office/principal place of business	Type of shares	Proportion of voting rights and shares held	Nature of business
American Proficiency Institute Group Inc	(1)	Ordinary	100	Food proficiency testing services
Analytical Reference Materials International Corp	(2)	Ordinary	100	Distribution of analytical reference standards
Aquacheck Limited	(3)	Ordinary	100	Dormant
Axolabs GmbH	(4)	Ordinary	100	Contract development and manufacturing of oligonucleotide therapeutics
Berry & Associates, Inc	(5)	Ordinary	100	Genomics products and services
BioAutomation Corporation	(6)	Ordinary	100	Genomics products and services
Biosearch Technologies Inc	(7)	Ordinary	100	Genomics products and services
Brand Reputation Compliance Limited	(3)	Ordinary	77.5	Holding company
BRC Global Standards (Americas) Corporation	(8)	Ordinary	77.5	Distribution of analytical reference standards
BRC GS America Inc	(9)	Ordinary	77.5	Distribution of analytical reference standards
BRC Trading Limited	(3)	Ordinary	77.5	Distribution of analytical reference standards
Cardiff Bioanalytical Services Limited	(3)	Ordinary	100	Dormant
Douglas Scientific LLC	(10)	Ordinary	55	Genomics products and services
Dr Ehrenstorfer GmbH	(11)	Ordinary	100	Distribution of analytical reference standards
Focus Forensic Telecommunications Limited	(3)	Ordinary	100	Dormant
Forensic Alliance Limited	(3)	Ordinary	100	Dormant
HFL Sport Science Limited	(3)	Ordinary	100	Dormant
Industrial Analytical Pty Limited	(12)	Ordinary	100	Distribution of analytical reference standards
KBiosciences Limited	(3)	Ordinary	100	Dormant
Kirkegaard & Perry Laboratories, Inc	(13)	Ordinary	100	Dormant
LGC (Holdings) Limited	(3)	Ordinary	100	Holding company
LGC (North West) Limited	(3)	Ordinary	100	Holding company
LGC (Teddington) Limited	(3)	Ordinary	100	Holding company
LGC Beteiligungs GmbH	(11)	Ordinary	100	Holding company
LGC Bio Senate Limited	(3)	Ordinary	100	Dormant
LGC Bioresearch Limited	(3)	Ordinary	100	Dormant
LGC Biosearch GmbH	(14)	Ordinary	100	Genomics products and services

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

6. Investments (continued)

Subsidiary	Registered office/principal place of business	Type of shares	Proportion of voting rights and shares held	Nature of business
LGC Biosearch technologies A/S	(15)	Ordinary	100	Genomics products and services
LGC Coleshill Limited	(3)	Ordinary	100	Dormant
LGC Genomics GmbH	(16)	Ordinary	100	Genomics products and services
LGC Genomics Holding GmbH	(16)	Ordinary	100	Holding company
LGC Genomics Limited	(3)	Ordinary	100	Genomics products and services
LGC Genomics LLC	(1)	Ordinary	100	Genomics products and services
LGC Genomics US Holdings Inc	(1)	Ordinary	100	Holding company
LGC GmbH	(17)	Ordinary	100	Manufacture of analytical reference standards
LGC Group Holdings Limited	(3)	Ordinary	100	Holding company
LGC Holding GmbH	(16)	Ordinary	100	Holding company
LGC Investments GmbH	(11)	Ordinary	100	Holding company
LGC Investments Limited	(3)	Ordinary	100	Holding company
LGC Labor GmbH	(11)	Ordinary	100	Manufacture of analytical reference standards
LGC Limited	(3)	Ordinary	100	Chemical and biochemical analysis consultancy and distribution of analytical reference standards
LGC North America Inc	(1)	Ordinary	100	Holding company
LGC Rhone Inc	(1)	Ordinary	100	Holding company
LGC Science (Beijing) Co Limited	(18)	Ordinary	100	Distribution of analytical reference standards
LGC Science (Nanjing) Co Limited	(19)	Ordinary	100	Distribution of analytical reference standards
LGC Science (Shanghai) Co Limited	(20)	Ordinary	100	Distribution of analytical reference standards
LGC Science and Standards (India) Private Limited	(21)	Ordinary	100	Distribution of analytical reference standards
LGC Science Group (Singapore) Pte Limited	(22)	Ordinary	100	Holding company
LGC Science Holdings Limited	(3)	Ordinary	100	Holding company
LGC Science Investments Limited	(3)	Ordinary	100	Holding company
LGC Science Inc	(23)	Ordinary	100	Analytical testing services
LGC Science Limited	(3)	Ordinary	100	Dormant
LGC Standards (South Africa) (Proprietary) Limited	(12)	Ordinary	100	Holding company
LGC Standards Brazil Exportação E Importação Ltda	(24)	Ordinary	100	Distribution of analytical reference standards
LGC Standards GmbH	(11)	Ordinary	100	Distribution of analytical reference standards
LGC Standards Inc	(25)	Ordinary	100	Distribution of analytical reference standards
LGC Standards Sarl	(26)	Ordinary	100	Distribution of analytical reference standards
LGC Standards SL	(27)	Ordinary	100	Distribution of analytical reference standards
LGC Standards Spzoo	(28)	Ordinary	100	Distribution of analytical reference standards
LGC Standards Srl	(29)	Ordinary	100	Distribution of analytical reference standards

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

6. Investments (continued)

Subsidiary	Registered office/principal place of business	Type of shares	Proportion of voting rights and shares held	Nature of business
LGC Whirlwind Ltd	(3)	Ordinary	100	Holding company
Link Technologies Limited	(30)	Ordinary	100	Genomics products and services
Lucigen Corporation	(31)	Ordinary	100	Genomics products and services
Maine Standards Company LLC	(32)	Ordinary	100	Manufacture of analytical reference standards
MBH Analytical Limited	(3)	Ordinary	100	Manufacture of certified reference materials
Organic Standard Solutions International LLC	(33)	Ordinary	100	Distribution of analytical reference standards
Prime Synthesis Inc	(34)	Ordinary	100	Genomics products and services
Project Plasma Holdings Corporation	(35)	Ordinary	100	Holding Company
Promochem Limited	(3)	Ordinary	100	Dormant
Quality Management Holdings Limited	(3)	Ordinary	100	Holding company
Quality Management Limited	(3)	Ordinary	100	Dormant
SeraCare Life Sciences, Inc	(36)	Ordinary	100	Manufacture of certified reference and clinical diagnostic materials
Teddington 2 Limited	(3)	Ordinary	100*	Holding company
Thistle Laboratory Services (Proprietary) Limited	(12)	Ordinary	100	Analytical testing services
University Diagnostics Limited	(3)	Ordinary	100	Dormant
VHG Labs Inc	(37)	Ordinary	100	Distribution of analytical reference standards

* Directly held by the Company

The country of incorporation matches the country in which the registered office/principal place of business is located

Key to registered office/principal place of business

- (1) National Registered Agents, Inc, 160 Greentree Drive, Suite 101, Dover DE 19904, United States
- (2) National Registered Agents, Inc, 1021 Main Street, 1150, Houston TX 77002, United States
- (3) LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom
- (4) Fritz-Hornschuch-Straße 9, D-95326 Kulmbach Germany
- (5) 2434 Bishop Circle E, Dexter Michigan, 48130, United States
- (6) National Registered Agents Inc, 701 S Carson St, Ste 200, Carson City, 89701, Nevada, United States
- (7) National Registered Agents, Inc, 818 W Seventh Street, Suite 930, Los Angeles CA 90017, United States
- (8) Cogency Global Inc 850 New Burton Road Suite 201 Dover DE 19904, United States
- (9) 15 Martin Street, Suite 202, Milton, ON L9T 2R4
- (10) 1010 Dale St N, St Paul, MN 55117-5603, USA
- (11) Mercatorstr 51, 46485 Wesel, Germany
- (12) 48 Monte Carlo Crescent, Kyalami Business Park, Kyalami, Gauteng, 1684, South Africa
- (13) The Corporation Trust Inc, 2405 York Road, Suite 201, Lutherville, Timonium MD, 21093-2264
- (14) Sonneberger Strasse 69, 96523 Steinach, Germany
- (15) Voldbjergvej 16B, 8240, Risskov, Denmark
- (16) Ostendstrasse 25, TGS Haus 8, 12459 Berlin, Germany

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

6. Investments (continued)

Key to registered office/principal place of business

- (17) Louis-Pasteur-Str 30, 14943, Luckenwalde, Germany
- (18) Room 110, Unit 3, No 6 Building, No 88 Yark, Kechuang Sixth Street, Beijing China
- (19) 5F, Block A5, Hongfeng Science Park, Economic and Technological Development Zone, Nanjing
- (20) Room 1577B, No 55 Xili Road, Shanghai Free Trade Zone, Shanghai, China
- (21) Unit No 216, Commercial Building Square One, C-2 District Centre, Saket, New Delhi, 110017, India
- (22) 50 Raffles Place, #32-01 Singapore Land Tower, Singapore 048623, Singapore
- (23) Northwest Registered Agent Service, Inc, 1521 Concord Pike, Suite 202, Wilmington DE 19803, United States
- (24) Avenida Salmão 663, Sala 66, Jardim Aquarius - São José Dos Campos, 12246-260 Brazil
- (25) National Registered Agents, Inc, 155 Federal Street, Suite 700, Boston MA 02110, United States
- (26) 6 rue Alfred Kastler, 67120 Molsheim, France
- (27) Salvador Espriu 59, 08005 Barcelona, Spain
- (28) ul M Konopnickiej 1, Dziekanów Leśny, 05-092, Łomianki, Poland
- (29) Via Tintoretto n 5, 20145 Milano, Italy
- (30) 3 Mallard Way, Strathclyde Business Park, Bellshill, Lanarkshire, ML4 3BF
- (31) Cogency Global, Inc , 901 S Whitney Way, Madison, WI, 53711 - 2553
- (32) 221 US Route 1, Cumberland Foreside, ME 04110, United States
- (33) National Registered Agents Inc , 2 Office Park Court, Columbia SC 29223, United States
- (34) 2 New Road, Suite 126, Aston DE 19014 United States
- (35) National Registered Agents Inc, 160 Greentree Drive, Suite 101, Dover, Kent, 19904, Delaware, United States
- (36) The Corporation Trust Company, Corporation Trust Center, 1209 Orange ST, Wilmington, DE, 19801, United States
- (37) National Registered Agents Inc, 276 Abby Road, Manchester NH 03103, United States

7. Debtors

	2019	2018
	£000	£000
Amounts owed by Group undertakings	2,533	2,353
Other receivables	40	40
	2,573	2,393

The loans owed by Group undertakings bear interest at rates of 8% (2018 - 8%) per annum and are repayable on demand

8. Creditors: amounts falling due within one year

	2019	2018
	£000	£000
Amounts due to Group undertakings	2,203	2,227

The loans due to Group undertakings bear interest at rates of 8% (2018 - 8%) per annum and are repayable on demand

9. Creditors: amounts falling due after more than one year

	2019	2018
	£000	£000
Amounts due to Group undertakings	111,414	103,161

The loans due to Group undertakings bear interest at rates of 8% (2018 - 8%) per annum

LGC Science Group Limited

Notes to the financial statements

at 31 March 2019

10. Share capital

Allotted and issued share capital

	2019	2018	2019	2018
	Number	Number	£000	£000
Ordinary shares of £0.01 each	16,109,058,620	16,109,058,620	161,091	161,091
	16,109,058,620	16,109,058,620	161,091	161,091

11. Commitments and guarantees

Guarantees

The Company and other subsidiaries have provided guarantees and granted security to support the syndicated bank borrowing arrangements of the Group.

12. Related party transactions

The Company has taken advantage of the exemption available under FRS101 not to disclose compensation of key management personnel and not to disclose related party transactions with other members of the Group.

There have been no transactions during the year (2018: £nil) with Directors or subsidiaries which are not 100% owned by the Group.

13. Ultimate holding company and controlling party

The Company's immediate parent company is LGC Science Group Holdings Limited. The smallest group of undertakings for which group accounts are drawn up and of which the Company is a member is LGC Science Group Holdings Limited, which are available to the public and may be obtained from LGC, Queens Road, Teddington, Middlesex, TW11 0LY. The largest group of undertakings for which group accounts are drawn up and of which the Company is a member is Elwy 2 Limited, which are available to the public and may be obtained from LGC, Queens Road, Teddington, Middlesex, TW11 0LY.

The majority shareholders of Elwy 2 Limited are KKR Fund Holdings L.P. and KKR European Fund IV L.P. (the "Funds"). Kohlberg Kravis Roberts & Co. L.P., a registered investment adviser regulated by the United States Securities & Exchange Commission (Registration NO. 90169634) under the U.S. Investment Advisors Act of 1940, acts as a manager for and on behalf of the Funds. No individual investor in the Funds has more than 25% of the interest in Elwy 2 Limited. The ultimate parent company of KKR Fund Holdings L.P. and KKR European Fund IV L.P. is KKR & Co. L.P., an entity incorporated in the United States of America.

14. Post balance sheet events

On 20 November 2019 the shareholders' of LGC agreed to the sale of LGC to a consortium jointly lead by Astorg and Cinven.